Introducing the Dual Prevention Pill (DPP) will require integration of contraception and PrEP in guidelines, health systems, delivery approaches, and demand creation. Join us to discuss how programs should think about rolling out novel prevention products like the DPP in the current landscape, learning from projects across sub-Saharan Africa.
Moderator
Isolde Birdthistle, London School of Hygiene & Tropical Medicine
Innovative HIV Prevention and Treatment Keynote and Panel Discussion
An in-depth discussion on lenacapavir, this session will examine its potential to transform HIV prevention on a global scale, looking at the latest clinical evidence, regulatory pathways, and the access barriers that may shape its rollout, especially in low-resource settings. The program will feature a special keynote address followed by a panel discussion with leading experts in HIV prevention and global health, exploring how innovation, policy, and equity intersect in the next frontier of HIV response.
Keynote Session
Moupali Das, MD, MPH, Gilead Sciences
Keynote Moderator: Dr. Charles B. Holmes, Director, Georgetown University Center for Innovation in Global Health; Distinguished Scholar and Program Director·O’Neill Institute for National and Global Health Law at Georgetown University Law Center
Panel Discussion
Moderator: Martha Sichone Cameron, PhD Candidate, Global Infectious Disease, Georgetown University
Micheal Ighodaro, Executive Director, Global Black Gay Men Connect (GBGMC)
Rupa Patel, MD, MPH, Clinical Researcher, Whitman Walker Institute
Mitchell Warren, Executive Director, AVAC
Avac Event
Beyond Borders
Join ISSTDR, IUSTI, the STI & HIV 2025 World Congress, and AVAC for a special webinar spotlighting speakers who were not about to join the congress due to financial and political barriers. Presenters will share their findings, debate their results, and discuss the work still ahead for the STI field. Don’t miss this opportunity to engage directly with cutting-edge research and the people driving it forward.
Avac Event
The Lancet’s Innovations in Sexual & Reproductive Health
Professor Kenneth Mayer (Fenway Health/Harvard Medical School/Harvard University Center for AIDS Research) and Prof. Linda-Gail Bekker (Desmond Tutu Health Foundation/University of Cape Town) made remarks coinciding with the US launch of The Lancet’s series on sexual and reproductive health.
This series, supported by The Gates Foundation, brings together global experts to highlight innovations, challenges, and opportunities for improving sexual and reproductive health worldwide.
Harvard University Center for AIDS Research (CFAR) Grand Rounds “Synergy for Health: The Case for Combining HIV, Sexual and Reproductive Health Services” Presented by Prof. Linda-Gail Bekker
Community Response Featuring Adrianna Boulin, Director of Racial Equity, Social Justice, and Community Engagement at Fenway Health
Q & A with Audience
Avac Event
From Courtrooms to Communities: Funding Advocacy to Protect HIV Responses
Please note: registration is limited to representatives of funding and philanthropy serving organizations.
Advocacy is one of the most underfunded areas of HIV philanthropy—yet essential to defending rights and sustaining progress.
Join Funders Concerned About AIDS (FCAA) on Wednesday, November 12, 2025, from 10:00–11:30 AM EST for From Courtrooms to Communities: Funding Advocacy to Protect HIV Responses.
Moderator
Marvell L. Terry II, Funders Concerned About AIDS (FCAA)
Featured Speakers
S. Mandisa Moore O’Neal, Center for HIV Law & Policy (CHLP)
Mitchell Warren, AVAC
Edwin J. Bernard, HIV Justice Network
Together, they will explore how shifting legal and policy environments are shaping HIV responses, why bold and intersectional advocacy strategies matter, and where philanthropy can make catalytic investments to protect and advance progress.
Avac Event
We Declare—Turning “The People’s Declaration” Demands into Actions and Accountability on HIV
The People’s Declaration—currently with over 500 signatories, charts out a number of community priorities and demands—as noted below. The Choice Agenda, The Legacy Project, and a fabulous global panel discussed moving these demands into actions and accountability.
To date, the discourse surrounding these actions has focused largely on the devastation to grants, dollars, and institutions. Here, we center people instead—the communities who stand to suffer the harshest consequences of these actions. Here, we remind the world that the first letter in HIV stands for human.
We demand substantive, meaningful inclusion of community in every aspect of HIV research, from protocol development to study implementation to the dissemination of clinical trial results.
We demand diversity, equity, and inclusion amongst the scientific teams conducting HIV research.
We demand diversity, equity, and inclusion across all community stakeholder engagement activities.
We demand diversity, equity, and inclusion in the recruitment of clinical trial participants who accurately reflect the epidemic.
Brian Minalga, Office of HIV/AIDS Network Coordination (HANC)
Panelists
Adrian Williams, AW DEI Consulting Inc
Brian Macharia, Health GAP
JD Davids, JD Strategies, Patient Led Research Collaborative
Luciana Kamel, HIV Community Advocate, Brazil
Moses Supercharger, Joint Adherent Brothers and Sisters Against AIDS, Uganda
Rebecca Denison, Advocate, USA
Avac Event
Do Not Check That Box – Impacts From the Assault on Transgender Communities and DEI + Strategies to Sustain and Rebuild
Our panelists had an unflinchingly honest—and interactive—conversation assessing the impacts of the ongoing assault on transgender communities, gender affirming health care, data collection, and Diversity, Equity and Inclusion writ large. Strategies to restore trust, sustain programming, and rebuild from the ashes were explored.
Panelists:
Dr. Joseph Cherabie Washington University St. Louis
Dr. Melanie Thompson AIDS Research Consortium of Atlanta
Dr. Asa Radix New York City
Leigh-Ann van der Merwe Social, Health & Empowerment Feminist Collective, South Africa
PEPFAR launched its “Bridge Planning” process on September 5, with country plans due September 25 and approval by September 30. This fast timeline risks excluding community and civil society voices, despite their critical role in shaping effective, sustainable HIV responses. Reports indicate limited to no community participation in many African partner countries, undermining rights-based, participatory planning.
Eannaso is hosting this emergency webinar to convene stakeholders to strategize collective advocacy for meaningful civil society engagement in this urgent process.
Avac Event
Will Lenacapavir be a Lever or a Let-Down? Lessons, Resources and Considerations for Implementation in the United States
Approved in July, lenacapavir for PrEP has tremendous potential to increase access and engagement in the United States, reaching individuals who have been unable to embrace PrEP in its previous formulations. The Choice Agenda and the HIV BLUPrInt team for a deep dive into rolling out lenacapavir (Yeztugo) in the US. Speakers summarized lessons, previewed existing resources, and called for expanded research and practice models that use lenacapavir as a lever to increase HIV prevention access, empowerment, and reach.
